Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT02834884

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access — Recruiting • Oncology • NCT02834884.

📅 17 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT02834884
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Start
2017-05-03
ClinicaliQ Trial Snapshot
  • SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access — Recruiting • Oncology • NCT02834884.
  • What is being tested: SPECTA is a standardized biobank platform collecting high-quality annotated biological samples, imaging data, operative records, and patient-reported outcomes from cancer patients to enable biomarker discovery and support translational research across multiple cancer types.
  • Patient eligibility overview: The platform recruits cancer patients across various tumour types and disease stages, with structured collection of clinicopathological data, environmental assessments, and validated questionnaires to create a comprehensive, quality-assured research resource.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Eligibility Snapshot
  • * Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Oncology · 26 Aug 2026
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →